Sulf-2: An extracellular modulator of cell signaling and a cancer target candidate

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 9, 2010, Pages 935-949

  Rosen, Steven D ^a   Lemjabbar Alaoui, Hassan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FGF 2 signaling; HSPG; Lung cancer; Sulfatase; Wnt signaling

Indexed keywords

CETUXIMAB; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; HEPARIN; PI 88; PROTEOHEPARAN SULFATE; SULFATASE; SULFATASE 1; SULFATASE 2; UNCLASSIFIED DRUG; WNT PROTEIN;

CARCINOGENESIS; CARCINOGENICITY; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO CULTURE; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MUSCLE REGENERATION; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SULFATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASMS; SIGNAL TRANSDUCTION; SULFOTRANSFERASES;

EID: 77955464418     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.504718     Document Type: Review

References (111)

1. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;14:729-777 (Pubitemid 29449208)
2. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001;11:75-82 (Pubitemid 32144754)
3. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-1037 (Pubitemid 46676065)
4. Lamanna WC, Kalus I, Padva M, et al. The heparanome-the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol 2007;129:290-307 (Pubitemid 46529030)
5. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001;108:165-7
6. Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004;131:6009-6021 (Pubitemid 40123916)
7. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001;108:169-173 (Pubitemid 32656238)
8. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-361
9. Habuchi H, Habuchi O, Kimata K. Sulfation pattern in glycosaminoglycan: does it have a code? Glycoconj J 2004;21:47-52 (Pubitemid 39360740)
10. Blackhall FH, Merry CL, Davies EJ, et al. Heparan sulfate proteoglycans and cancer. Br J Cancer 2001;85:1094-1098
11. Powell AK, Yates EA, Fernig DG, et al. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004;14:17R-30R
12. Dhoot GK, Gustafsson MK, Ai X, et al. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001;293:1663-6 (Pubitemid 32807846)
13. Morimoto-Tomita M, Uchimura K, Werb Z, et al. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002;277:49175-49185 (Pubitemid 36014346)
14. Ohto T, Uchida H, Yamazaki H, et al. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage. Genes Cell 2002;7:173-185 (Pubitemid 34213362)
15. Morimoto-Tomita M, Uchimura K, Bistrup A, et al. Sulf-2, a pro-angiogeni heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005;7:1001-1010
16. Lamanna WC, Baldwin RJ, Padva M, et al. Heparan sulfate 6-O-endosulfatase discrete in vivo activities and functional co-operativity. Biochem J 2006;400:63-73 (Pubitemid 44763820)
17. Lum DH, Tan JH, Rosen SD, et al. Gene trap disruption of the mouse heparan sulfate 6-O-endosulfatase, Sulf2 Mol Cell Biol 2006;27:678-688
18. Ai X, Kitazawa T, Do A-T, et al. SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development 2007;134:3327-3338 (Pubitemid 350018433)
19. Holst CR, Bou-Reslan H, Gore BB, et al. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS ONE 2007;2:e575 (Pubitemid 351260206)
20. Langsdorf A, Do AT, Kusche-Gullberg M, et al. Sulfs are regulators of growth factor signaling for satellite cell differentiation and muscle regeneration. Dev Biol 2007;311:464-477 (Pubitemid 350046541)
21. Diez-Roux G, Ballabio A. Sulfatases and human disease. Annu Rev Genomics Hum Genet 2005;6:355-79 (Pubitemid 41397088)
22. Sardiello M, Annunziata I, Roma G, et al. Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. Hum Mol Genet 2005;14:3203-3217 (Pubitemid 41631295)
23. Waldow A, Schmidt B, Dierks T, et al. Amino acid residues forming the active site of arylsulfatase A. J Biol Chem 1999;274:12284-12288
24. Schmidt B, Selmer T, Ingendoh A, et al. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 1995;82:271-278.
25. Cosma MP, Pepe S, Annunziata I, et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 2003;113:445-456 (Pubitemid 36588748)
26. Dierks T, Dickmanns A, Preusser-Kunze A, et al. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell 2005;121:541-552 (Pubitemid 40720008)
27. Tang R, Rosen SD. Functional consequences of the subdomain organization of the Sulfs. J Biol Chem 2009;284:21505-21514
28. Nagamine S, Keino-Masu K, Shiomi K, et al. Proteolytic cleavage of the rat heparan sulfate 6-O-endosulfatase SulfFP2 by furin-type proprotein convertases. Biochem Biophys Res Commun 2010;391:107-112
29. Lamanna WC, Frese MA, Balleininger M, et al. Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem 2008;283:27724-27735
30. Nawroth R, van Zante A, Cervantes S, et al. Extracellular sulfatases, elements of the wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE 2007;2:e392
31. Lemjabbar-Alaoui H, van Zante A, Singer MS, et al. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010;29:635-646
32. Ai X, Do AT, Kusche-Gullberg M, et al. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem 2006;281:4969-4976 (Pubitemid 43847759)
33. Frese M-A, Milz F, Dick M, et al. Characterization of the human sulfatase sulf1 and its high-affinity heparin/ heparan sulfate interaction domain. J Biol Chem 2009;284:28033-28044
34. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010;327:46-50
35. Ai X, Do AT, Lozynska O, et al. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 2003;162:341-351 (Pubitemid 36928846)
36. Viviano BL, Paine-Saunders S, Gasiunas N, et al. Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem 2004;279:5604-5611 (Pubitemid 38220587)
37. Saad OM, Ebel H, Uchimura K, et al. Compositional profiling of heparin/heparan sulfate using mass spectrometry: assay for specificity of a novel extracellular human endosulfatase. Glycobiology 2005;15:818-826 (Pubitemid 41417984)
38. Uchimura K, Morimoto-Tomita M, Rosen SD. Measuring the activities of the sulfs: two novel heparin/heparan sulfate endosulfatases. Methods Enzymol 2006;416:243-253 (Pubitemid 44750114)
39. Nagase H, Fushimi K. Elucidating the function of non catalytic domains of collagenases and aggrecanases. Connect Tissue Res 2008;49:169-174
40. Uchimura K, Morimoto-Tomita M, Bistrup A, et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006;7:2 (Pubitemid 43326828)
41. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810 (Pubitemid 39488658)
42. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-398 (Pubitemid 351589714)
43. Kalus I, Salmen B, Viebahn C, et al. Differential involvement of the extracellular 6-O-endosulfatases Sulf1 and Sulf2 in brain development and neuronal and behavioural plasticity. J Cell Mol Med 2009;13:4505-4521
44. Ratzka A, Kalus I, Moser M, et al. Redundant function of the heparan sulfate 6-O-endosulfatases Sulf1 and Sulf2 during skeletal development. Dev Dyn 2008;237:339-353 (Pubitemid 351312107)
45. Lai J, Chien J, Staub J, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003;278:23107-23117 (Pubitemid 36830377)
46. Lai JP, Chien J, Strome SE, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004;23:1439-1447 (Pubitemid 38406839)
47. Lai JP, Chien JR, Moser DR, et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004;126:231-248
48. Dai Y, Yang Y, MacLeod V, et al. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 2005;280:40066-40073 (Pubitemid 41779141)
49. Li J, Kleeff J, Abiatari I, et al. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 2005;4:14 (Pubitemid 41460844)
50. Yue X, Li X, Nguyen HT, et al. Transforming growth factor-{beta} 1 induces heparan sulfate 6-O-endosulfatase 1 expression in vitro and in vivo. J Biol Chem 2008;283:20397-20407
51. Wang S, Ai X, Freeman SD, et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 2004;101:4833-4838 (Pubitemid 38469163)
52. Morimoto-Tomita M, Uchimura K, Rosen SD. Novel extracellular sulfatatases: potential roles in cancer. Trends Glycosci Glycotechnol 2003;15:159-164 (Pubitemid 36928461)
53. Grigoriadis A, Mackay A, Reis-Filho JS, et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res 2006;8:R56 (Pubitemid 44698287)
54. Castro NP, Osorio CA, Torres C, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008;10:R87
55. Kudo Y, Ogawa I, Kitajima S, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 2006;66:6928-6935 (Pubitemid 44197667)
56. Junnila S, Kokkola A, Mizuguchi T, et al. Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes Chromosomes Cancer 2010;49:28-39
57. Lai JP, Sandhu DS, Yu C, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008;47:1211-1222 (Pubitemid 351547907)
58. Tatrai P, Egedi K, Somoracz A, et al. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem 2010;58:429-441
59. Staub J, Chien J, Pan Y, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 2007;26:4969-4978 (Pubitemid 47172647)
60. Backen AC, Cole CL, Lau SC, et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer 2007;96:1544-1548
61. Johansson FK, Brodd J, Eklof C, et al. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci USA 2004;101:11334-11337 (Pubitemid 39038347)
62. Johansson FK, Goransson H, Westermark B. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 2005;24:3896-3905 (Pubitemid 40896401)
63. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274 (Pubitemid 44571966)
64. Pasca di Magliano M, Biankin AV, Heiser PW, et al. Common activation of canonical wnt signaling in pancreatic adenocarcinoma. PLoS ONE 2007;2:e1155
65. Sato M, Shames DS, Gazdar AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-343 (Pubitemid 47181718)
66. Minna JD. Neoplasms of the lung. In: Kasper DL, Braunwald E, Fauci AS, et al., editors. Harrison's principles of internal medicine (Chapter 75). 16th edition (online edition) McGraw Hill Professional, Chicago, IL, USA; 2006
67. Lemjabbar-Alaoui H, Dasari V, Sidhu SS, et al. Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS ONE 2006;1:e93
68. Mazieres J, He B, You L, et al. Wnt signaling in lung cancer. Cancer Lett 2005;222:1-10 (Pubitemid 40544841)
69. Akiri G, Cherian MM, Vijayakumar S, et al. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 2009;28:2163-2172
70. Lai JP, Sandhu DS, Shire AM, et al. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer 2008;39:149-158
71. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-837
72. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-129
73. Marek L, Ware KE, Fritzsche A, et al. Fibroblast growth factor (FGF) and FGR receptor mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009;75:196-207
74. Kim CF, Jackson EL, Kirsch DG, et al. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol 2005;70:241-250 (Pubitemid 44124878)
75. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379-384 (Pubitemid 46310172)
76. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 2004;22:1-6
77. Vlodavsky I, Ilan N, Naggi A, et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007;13:2057-2073 (Pubitemid 47044735)
78. Hossain MM, Hosono-Fukao T, Tang R, et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology 2010;20:175-186
79. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs 2008;17:1769-1776
80. Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal 2004;4:589-604
81. Schuger L, Johnson GR, Gilbride K, et al. Amphiregulin in lung branching morphogenesis: interaction with heparan sulfate proteoglycan modulates cell proliferation. Development 1996;122:1759-1767 (Pubitemid 26192741)
82. Schlange T, Matsuda Y, Lienhard S, et al. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007;9:R63
83. Steiner P, Joynes C, Bassi R, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007;13:1540-1551 (Pubitemid 46450446)
84. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-789 (Pubitemid 46622045)
85. French PJ, Swagemakers SM, Nagel JH, et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005;65:11335-11344 (Pubitemid 41821690)
86. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527 (Pubitemid 351655218)
87. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007;7:55 (Pubitemid 46605012)
88. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563
89. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-132 (Pubitemid 43202662)
90. Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131 (Pubitemid 351916552)
91. Ki DH, Jeung HC, Park CH, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007;121:2005-2012 (Pubitemid 47463164)
92. Chen X, Leung SY, Yuen ST, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 2003;14:3208-3215 (Pubitemid 37013121)
93. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004;64:55-63 (Pubitemid 38114082)
94. Toruner GA, Ulger C, Alkan M, et al. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004;154:27-35 (Pubitemid 39286169)
95. Gumz ML, Zou H, Kreinest PA, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007;13:4740-4749 (Pubitemid 47294780)
96. Cutcliffe C, Kersey D, Huang CC, et al. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 2005;11:7986-7994 (Pubitemid 41698739)
97. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. PNAS 2001;98:13790-13795 (Pubitemid 33115977)
98. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008;3:e1651 (Pubitemid 351865456)
99. Su LJ, Chang CW, Wu YC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007;8:140
100. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005;167:1763-1775 (Pubitemid 41713326)
101. Talbot SG, Estilo C, Maghami E, et al. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res 2005;65:3063-3071 (Pubitemid 40524586)
102. Riker AI, Enkemann SA, Fodstad O, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008;1:13
103. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003;162:1151-1162 (Pubitemid 36350660)
104. Segara D, Biankin AV, Kench JG, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005;11:3587-3596 (Pubitemid 40627916)
105. Detwiller KY, Fernando NT, Segal NH, et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 2005;65:5881-5889 (Pubitemid 40911194)
106. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005;166:1827-1840
107. Korkola JE, Houldsworth J, Chadalavada RS, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006;66:820-827 (Pubitemid 43165947)
108. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403 (Pubitemid 43668737)
109. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300
110. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007;67:4605-4619 (Pubitemid 46910165)
111. Yusenko MV, Kuiper RP, Boethe T, et al. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 2009;9:152